Longeveron (LGVN) Short term Debt (2021 - 2023)

Longeveron (LGVN) recorded quarterly Short term Debt of $586000.0 in Q3 2023, up 1.38% quarter-over-quarter from $578000.0 in Q2 2023.

Longeveron (LGVN) Short term Debt (2021 - 2023) Analysis & Trends

Longeveron's Short term Debt history runs 3 years deep, the most recent figure standing at $586000.0 for Q3 2023.

  • In Q3 2023, Short term Debt changed N/A year-over-year to $586000.0; the TTM figure through Sep 2023 stood at $586000.0 (changed N/A YoY), while the FY2022 annual figure was $564000.0, up 5.03% from the prior year.
  • Short term Debt was $586000.0 for Q3 2023 at Longeveron, up from $578000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $586000.0 in Q3 2023 to a low of $537000.0 in Q4 2021.
  • Historically, Short term Debt has averaged $567200.0 across 3 years, with a median of $571000.0 in 2023.
  • Biggest YoY gain for Short term Debt was 5.03% in 2022; the steepest drop was 5.03% in 2022.
  • A 3-year view of Short term Debt shows it stood at $537000.0 in 2021, then advanced by 5.03% to $564000.0 in 2022, then advanced by 3.9% to $586000.0 in 2023.
  • The last three Short term Debt figures came in at $586000.0 (Q3 2023), $578000.0 (Q2 2023), and $571000.0 (Q1 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00

Historic Data

Download Data
DateValue
Sep 30, 2023 586,000.00
Jun 30, 2023 578,000.00
Mar 31, 2023 571,000.00
Dec 31, 2022 564,000.00
Dec 31, 2021 537,000.00